New injection known as “Ecnoglutide” has shown promising results as a treatment for type 2 diabetes and obesity, and this may provide a new competitor to drugs such as Uzbek.
The study was conducted by researchers from the University of Vodan and Hangzhou Sind Biological Sciences in China and published its results in “The Lancet Diabets & Endocrinology” on August 22, and the American Journal of Newsweek was written about it.
The researchers discovered that Eccooticide works with the same effectiveness of dolglotide (a syringe usually described once a week for diabetes management) in lowering blood sugar levels.
Eckenoglotide-who has not yet been authorized-and Dolglotide regulates blood sugar levels by affecting the same future in the body, known as the future of glucagon-1 peptide, and the researchers said that Aknoglotide may help patients lose a greater weight than dolglotide.
The researchers pointed out that Aquaglotide targets specific paths in the body that enhance insulin production and reduce blood sugar, while avoiding another path that can sometimes reduce future activity. Dolglotide does both tracks with the same extent.
Best control and easier industry
“Eckenoglotide is a better effectiveness in losing weight and controlling blood sugar compared to the drugs used in clinical trials,” Fifi Jiang, author of the study, told Newsweek.
The study lasted 52 weeks, and included more than 600 adults with type 2 diabetes in China, average blood sugar in the participants who consumed Eckenoglotide decreased by about 1.9%, compared to a decrease of 1.65% in the participants who consumed dolglotide, as well as people who consumed Akcoglotide as much as the weight of those who have eaten dolglootide.
It is expected based on the available information so far that the types of side effects associated with Kenglotide are similar to those of the current peptide-like receptors-1 (such as Simiglotide or Dolglotide), including mainly the digestive disorders (diarrhea, nausea, vomiting) and loss of appetite, and most cases were light side effects, and they tend to decrease Gradually with prolonged treatment.
The study also highlights that the production of Eccooticide is easier than the production of other virus-like peptide-1 receptors, and this means that it can be manufactured more quickly and at a lower cost than other weight loss medications currently available.